The position of tiotropium in new treatment guidelines for chronic obstructive pulmonary disease
Authors:
V. Koblížek
Authors‘ workplace:
Plicní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MUDr. František Salajka, CSc.
Published in:
Vnitř Lék 2013; 59(12): 1073-1080
Category:
Review
Overview
Chronic obstructive pulmonary disease is a significant syndrome of internal medicine with serious health, social and economic impacts. Globally, tiotropium is the longest used and through the randomised studies the most examined representative of inhalation long-acting antimuscarinics. In routine practice, this treatment group is identified with a globally known abbreviation LAMA (or U-LAMA, U means ultralong-acting with dosing every 24 hours). Pharmacological agents of the LAMA (U-LAMA) group are included in a significant number of all important treatment guidelines. The Czech guidelines place these medicines into the first line of general medication – for all symptomatic patients, regardless of the stage, age and comorbidities. The article describes the role of LAMA (namely tiotropium) in the treatment of chronic obstructive pulmonary disease and also relevant evidence of the efficacy and safety of both tiotropium dosage forms (HandHaler and Respimat) in detail.
Keywords:
chronic obstructive pulmonary disease (COPD) – treatment guidelines – LAMA – tiotropium
Sources
1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613–620.
2. Hooper R, Burney P, Vollmer WM et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39: 1343–1353.
3. Koblížek V, Chlumský J, Zindr V et al. Chronic obstructive pulmonary disease in the light of new guidelines – brief summary of phenotypically oriented guidelines for nonpulmonary physicians. Vnitř Lék 2013; 59: 505–514.
4. Miravitlles M, Soler‑Cataluña JJ, Calle M et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012; 48: 247–257.
5. Hronek M, Kovarik M, Aimova P et al. Skinfold anthropometry-the accurate method for fat free mass measurement in COPD. COPD 2013; 10: 597–603.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. 2013 Feb [cited 2013 Nov 2]. Available from: http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
7. Lamprecht B, McBurnie MA, Vollmer WM et al. COPD in never smokers: results from the population‑based burden of obstructive lung disease study. Chest 2011; 139: 752–763.
8. Malý M, Zvolský M, Rozborilová E et al. Respiratory Mortality in Czech and Slovak Republics in the year 2011. Stud Pneumol Phtiseol 2013; 73: 128–132.
9. Vondra V Úmrtnost na CHOPN v letech 1996–2005 se zdvojnásobila. Stud Pneumol Phtiseol 2007; 67: 75.
10. Institute of Medical Information Services. Tuberculosis and respiratory diseases 2011. 2012 Nov [cited 2013 Nov 2] Available from: http://www.uzis.cz/katalog/zdravotnicka‑statistika/tuberkuloza‑respiracni‑nemoci.
11. Hooper R, Burney P, Vollmer WM et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39: 1343–1353.
12. Bryant J, McDonald V, Boyes A et al. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res 2013; 14: 109.
13. Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. Ann Intern Med 2011; 155: 179–191.
14. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (updated) Clinical guidelines CG101. 2013 Mar [cited 2013 Nov 2]. Available from: http://www.nice.org.uk/CG101.
15. Celli BR. Update on the management of COPD. Chest 2008; 133: 1451–1462.
16. Czech Pneumological and Phthisiological Society. Guidelines for indication of home long term oxygen therapy 2013. 2013 Apr [cited 2013 Nov 2]. Available from: http://www. pneumologie.cz/odborne/doc/Standard%20 DDOT‑ %20final.pdf.
17. O'Donnell DE, Aaron S, Bourbeau J et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J 2007; 14: (Suppl B): 5B–32B.
18. Lange P, Marott JL, Vestbo J et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975–981.
19. Celli BR, Cote CG, Marin JM et al. The body‑mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012.
20. Anthoniesen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5‑year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–239.
21. Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010; 8: 84.
22. Troosters T, Molen T, Polkey M et al. Improving physical activity in COPD: towards a new paradigm. Respir Res 2013; 14: 115.
23. Decramer M, Celli BR, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT) a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
24. Mahler DA, D’Urzo A, Bateman ED et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilatation compared with tiotropium alone: a randomised, double‑blind comparison. Thorax 2012; 67: 781–788.
25. Tashkin DP, Fabbri LM Long‑acting beta‑agonist in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149.
26. Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double‑blind, parallel‑group study. Lancet Respir Med 2013; 1: 199–209.
27. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbation of COPD. N Engl J Med 2011; 364: 1093–1103.
28. Calverley PM, Anderson JA, Celli BR et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789.
29. Miravitlles M, Calle M, Soler‑Cataluña JJ. Clinical phenotypes of COPD. Identification, definition and implications for quidelines. Arch Broncopneumol 2012; 48: 86–98.
30. Kerstjens H, Engel M, Dahl R et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198–1207.
31. Wells JM, Dransfield MT. Pathophysiology and clinical implication of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis 2013; 8: 509–521.
32. Beeh K, Glaab T, Stowasser S et al. Characterization of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res 2013; 14: 116.
33. Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 625–626.
34. Izquierdo‑Alonso JL, Rodriguez‑Gonzálezmoro JM, de Lucas‑Ramos P et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013; 107: 724–731.
35. Nava S, Sturani C, Hartl S et al. End‑of‑life decision – making in respiratory intermediate care units: a European survey. ERS TASK FORCE. Eur Respir J 2007; 30: 156–164.
36. Lanken PN, Terry PB, DeLisser HM et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177: 912–927.
37. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on the rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332–338.
38. Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‑controlled TORCH study. Respir Res 2009; 10: 59.
39. Laube BL, Janssens HM, Jongh FH et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308–1331.
40. O’Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–840.
41. Decramer ML Chapman KR, Dahl R et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524–533.
42. Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817.
43. Kesten S, Casaburi R, Kukafka D et al. Improvement in self‑reported exercise participation with combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008; 3: 127–136.
44. Singh S, Loke YK, Enright PL et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta‑analysis of randomised controlled trials. BMJ 2011; 342: d3215.
45. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium the FDA’s conclusions. N Engl J Med 2010; 363: 1097–1099.
46. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Tiotropium Respimat Pharmacokinetic Study in COPD[cited 2013 Nov 4] Available from: http://www.clinicaltrials.gov/ct2/show/NCT01222533.
47. Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491–1501.
48. Matejovska-Kubesova H, Weber P, Meluzinova H et al. Senioři a kardiovaskulární medikace. Vnitř Lék 2011; 57: 561–570.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2013 Issue 12
Most read in this issue
- Contemporary view on liver impairment in heart failure
- Histiocytic sarcoma
- Serious risk related to oral use of sodium phosphate solution
- Inflammatory borrelia – associated dilated cardiomyopathy